Working with international partners, scientists across PSI and OVG will design and develop multivalent vaccine candidates with funding from CEPI and Horizon Europe.
PSI\u2019s Nipah Virus Research Day, held on Wednesday, 19 November 2025, showcased promising developments, spanning new insights into Nipah virus biology, clinical trials of vaccines, the development of policy responses, and progress in developing diagnostics and treatments, all of which are helping improve responses to outbreaks of this deadly virus.
A landmark international research collaboration has launched the largest clinical trial ever conducted to test therapeutics for moderate-severe dengue, a mosquito-borne viral disease that continues to spread rapidly driven by climate change and globalisation.
The trial will assess the safety and immune response of the ChAdOx1 NipahB vaccine, developed by PSI scientists, in a region where the virus causes recurrent outbreaks.
The vaccine developed by PSI researchers aims to advance the fight against Lassa fever virus, a WHO priority pathogen posing a significant public health risk.
The analysis draws on data aggregated through the amr.watch platform, created by PSI's Centre for Genomic Pathogen Surveillance to build more equitable and effective genomic surveillance worldwide.
PSI colleagues Professor Alice Norton, Professor Samantha Vanderslott and Professor Sir Peter Horby reflect on what the WHO Pandemic Agreement means for the UK, in a BMJ editorial.
Two new papers from University of Oxford scientists have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
Researchers from the UK and Madagascar, in collaboration with Madagascar\u2019s health services and national plague programme, have conducted the world\u2019s first rigorous clinical trial of treatments for bubonic plague.
Hosted by the Centre for Genomic Pathogen Surveillance at PSI, the new Centre will support efforts to tackle one of the most pressing global health challenges of our time.
The visit to the Clinical BioManufacturing Facility and the laboratories of the Oxford Vaccine Group and Pandemic Sciences Institute showcased Oxford\u2019s global leadership in medical science and innovation.
The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford\u2019s mission to counter and constrain global health threats.
The designation recognises the vaccine\u2019s potential to address the unmet medical need arising from the devastating Nipah virus disease, which can be fatal in up to 85% of cases.
This honour comes in recognition of Mr El Muhanna's outstanding contributions to the field of biomanufacturing and his contributions to international patents.
The new RAPID Stigma Scales, led by researchers at the PSI, will help health professionals to monitor stigma in disease outbreak settings, improving outbreak responses globally.
![\"\"](\"https://www.psi.ox.ac.uk/news-and-opinion/ambitious-research-aiming-to-develop-multivalent-vaccines-to-protect-against-multiple-deadly-filoviruses/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n